News CMS's Medicare price negotiations start round three The US federal government has named the next 15 big-selling medicines that will be subject to Medicare pricing negotiations.
News 'Skinny' generic Vascepa label case reaches US Supreme Court SCOTUS has agreed to hear a patent dispute between Amarin and Hikma that could have implications for 'skinny labels' used by generic manufacturers.
Market Access US pharma MFN and tariff dynamics: What EU and UK leaders ne... Europe and the United Kingdom are entering a period of direct exposure to US policy choices, and the implications are significant and immediate.
News Trump's affordability plan arrives, built around MFN pricing Trump has finally delivered his healthcare proposals, but it seems the 'concept of a plan' promised for many years remains pretty much just that.
Market Access Changes to UK’s VPAG: Non-submissions should be a key metric... Whatever people think of changes to the UK’s pricing deal, VPAG, judging the difference they make should include monitoring non-submissions to NICE.
News AbbVie turbocharges its US investment promise to $100bn AbbVie finally agrees a Most-Favoured Nation pricing deal with the US administration, with a $100 billion investment promise attached.
R&D Allogeneic cell therapy isn’t dead, with Brian Culley Lineage Cell Therapeutics' Brian Culley discusses allogeneic cell therapy, even beyond the traditional cell therapy realm of oncology.
Sales & Marketing Sponsored How to meet your physicians where they are online A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
